These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6861263)

  • 21. Phase I study of NKT-01.
    Tamura K; Niitani H; Oguro M; Ohno R; Sanpi K; Majima H; Masaoka T; Kimura I; Inagaki J; Suzuoki Y
    Cancer Chemother Pharmacol; 1995; 36(3):189-94. PubMed ID: 7781137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of diaziquone in patients with colon cancer.
    Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
    Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
    Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
    Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
    Weick JK; Jones SE; Ryan DH
    Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
    Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
    Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of 4'-deoxydoxorubicin given weekly.
    Sessa C; Bosia L; Kaplan S; Pusterla C; Varini M; Cavalli F
    Invest New Drugs; 1984; 2(4):369-73. PubMed ID: 6511241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I clinical and pharmacokinetic trial of hepsulfam.
    Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
    Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
    Hansen SW; Bach F; Hansen HH; Kaplan S; Cavalli F
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):301-5. PubMed ID: 4007009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
    Postmus PE; Mulder NH; Grampel JC; Meyers WH; Berendsen HH
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1207-8. PubMed ID: 2820748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
    Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of intravenous menogaril administered intermittently.
    Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
    J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
    Abele R; Alberto P; Seematter RJ; Germano G; Heintz R; Bollag W
    Cancer Treat Rep; 1982 Jun; 66(6):1307-13. PubMed ID: 6211232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.